Suppr超能文献

耳局部应用糖皮质激素导致下丘脑-垂体-肾上腺轴反应及肝功能降低的证据。

Evidence for ototopical glucocorticoid-induced decrease in hypothalamic-pituitary-adrenal axis response and liver function.

作者信息

Abraham Getu, Gottschalk Jutta, Ungemach Fritz Rupert

机构信息

Leipzig University, Institute of Pharmacology, Pharmacy, and Toxicology, An den Tierkliniken 15, D-04103 Leipzig, Germany.

出版信息

Endocrinology. 2005 Jul;146(7):3163-71. doi: 10.1210/en.2005-0080. Epub 2005 Mar 31.

Abstract

To clarify whether ototopical glucocorticoid treatment is associated with impaired hypothalamic-pituitary-adrenal axis (HPA) activity and altered hepatic metabolism, one commercially available dexamethasone-containing ointment was tested. At present, very little is known about the effects of ototopical glucocorticoid treatment on HPA and liver function. Ten beagle dogs received two daily therapeutic doses of dexamethasone (0.6 mg/ear) in the outer auditory canal for 21 d in a single-blind, placebo-controlled study. Resting cortisol concentrations were assessed before, during, and after treatment using an RIA system. Adrenal function and HPA feedback sensitivity were measured by a standard dose (250 microg) ACTH stimulation test. Serum biochemical and hematological parameters were measured, whether ototopical glucocorticoids affect hepatic function was studied, and blood cell counts were made. Ototopical dexamethasone treatment induced a marked suppression (to about 100%) of resting plasma cortisol concentrations below the placebo effect (P < 0.0001) within the first 11 d, and these remained reduced during the entire treatment period up to d 19. As well, an ACTH stimulation test found a markedly reduced rise in plasma cortisol concentrations (P = 0.0004). Concomitantly, significant increases in serum activities of alkaline phosphatase, gamma-glutamyl transferase, alanine transaminase, and aspartate transaminase were detected. Moreover, we found a significant reduction in differential leukocyte counts of eosinophils and lymphocytes, whereas neutrophils increased. Although cortisol levels and hematological parameters returned to baseline 7 d after treatment cessation, liver enzyme activities remained elevated. In conclusion, these findings suggest that after ototopical application, dexamethasone is sufficiently absorbed from the auditory canal to suppress HPA function as well as to alter metabolic and hemopoietic profiles. Thus, in long-term treatment of otitis externa or media, the systemic adverse suppression of HPA has to be considered in relation to stress exposure, whereas changes in serum enzyme activities may not be interpreted as hepathopathy.

摘要

为了阐明耳局部应用糖皮质激素治疗是否与下丘脑 - 垂体 - 肾上腺轴(HPA)功能受损及肝脏代谢改变有关,对一种市售的含地塞米松软膏进行了测试。目前,关于耳局部应用糖皮质激素治疗对HPA和肝功能的影响知之甚少。在一项单盲、安慰剂对照研究中,10只比格犬在外耳道接受每日两次治疗剂量的地塞米松(0.6 mg/耳),持续21天。使用放射免疫分析系统在治疗前、治疗期间和治疗后评估静息皮质醇浓度。通过标准剂量(250 μg)促肾上腺皮质激素(ACTH)刺激试验测量肾上腺功能和HPA反馈敏感性。测量血清生化和血液学参数,研究耳局部应用糖皮质激素是否影响肝功能,并进行血细胞计数。耳局部应用地塞米松治疗在最初11天内导致静息血浆皮质醇浓度显著抑制(降至约100%),低于安慰剂效应(P < 0.0001),并且在整个治疗期直至第19天一直保持降低。同样,ACTH刺激试验发现血浆皮质醇浓度升高明显降低(P = 0.0004)。同时,检测到碱性磷酸酶、γ-谷氨酰转移酶、丙氨酸转氨酶和天冬氨酸转氨酶的血清活性显著增加。此外,我们发现嗜酸性粒细胞和淋巴细胞的分类白细胞计数显著减少,而中性粒细胞增加。尽管治疗停止7天后皮质醇水平和血液学参数恢复到基线,但肝酶活性仍保持升高。总之,这些发现表明,耳局部应用后,地塞米松可从耳道充分吸收,抑制HPA功能并改变代谢和造血特征。因此,在外耳道炎或中耳炎的长期治疗中,必须考虑HPA的全身不良抑制与应激暴露的关系,而血清酶活性的变化可能不能解释为肝病。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验